Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
about
Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinomaEverolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapyTargeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus.Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysisThe ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.New advances in genitourinary cancer: evidence gathered in 2014.Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas.Recent advances in renal cell carcinoma from a pathological point of view.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice.Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors.Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.
P2860
Q26783514-DBBFC9D6-F7E0-4694-971E-F1BE5329C590Q28079861-AB9A87E5-4B93-45A6-A267-0279F5C1248AQ35063752-6909A0D4-1DBD-4E61-8FE1-D7F0CF2B49D7Q36190276-E4477536-A8AE-4A88-A597-9921D9ADDC91Q36729436-B670A14A-66FB-4EF4-AC3C-C44FBA1D35BBQ38527936-0F688158-BF5F-4365-B84E-22424F5D3E48Q38557894-FF2D3536-0AFB-4A36-96D9-971417C864B5Q38823442-40C17C33-9567-4D0C-9B65-B109DDFD685FQ38909760-74405F15-DEB7-4D98-8ADA-02D0936C8D93Q39008859-1F7F7A61-8E7B-465E-B026-97C6F3A22F56Q39097822-8D84AD9C-8224-4C83-ABC0-8239D839103DQ39379576-97401250-5FF2-4249-B9EB-2BFC70612AB2Q41746665-91F7DFF8-67FF-46BA-9224-C4BF4DB7F532Q42650839-84B60785-130A-425D-88E8-57D7CE7659D6Q47847243-00C54EEF-03B9-43EB-A3A8-FFCB96CEE105Q49571137-606A06A1-B948-49AD-853A-2FBBD77F4FF9Q52661828-0970DEA9-5CEE-4AA5-AED7-FFDEE18B54EA
P2860
Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phosphorylation of mTOR and S6 ...... tastatic renal cell carcinoma.
@ast
Phosphorylation of mTOR and S6 ...... tastatic renal cell carcinoma.
@en
type
label
Phosphorylation of mTOR and S6 ...... tastatic renal cell carcinoma.
@ast
Phosphorylation of mTOR and S6 ...... tastatic renal cell carcinoma.
@en
prefLabel
Phosphorylation of mTOR and S6 ...... tastatic renal cell carcinoma.
@ast
Phosphorylation of mTOR and S6 ...... tastatic renal cell carcinoma.
@en
P2093
P2860
P356
P1433
P1476
Phosphorylation of mTOR and S6 ...... tastatic renal cell carcinoma.
@en
P2093
Chuanliang Cui
Xinan Sheng
Zhihong Chi
P2860
P2888
P356
10.1186/1471-2407-14-376
P407
P577
2014-05-28T00:00:00Z
P5875
P6179
1033466073